19 analysts have shared their evaluations of Exact Sciences (NASDAQ:EXAS) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 13 | 6 | 0 | 0 | 0 |
| Last 30D | 2 | 0 | 0 | 0 | 0 |
| 1M Ago | 10 | 4 | 0 | 0 | 0 |
| 2M Ago | 0 | 1 | 0 | 0 | 0 |
| 3M Ago | 1 | 1 | 0 | 0 | 0 |
Insights from analysts' 12-month price targets are revealed, presenting an average target of $75.37, a high estimate of $95.00, and a low estimate of $60.00. A 3.95% drop is evident in the current average compared to the previous average price target of $78.47.
Investigating Analyst Ratings: An Elaborate Study
An in-depth analysis of recent analyst actions unveils how financial experts perceive Exact Sciences. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Dan Brennan | TD Cowen | Raises | Buy | $86.00 | $82.00 |
| Mark Massaro | BTIG | Raises | Buy | $75.00 | $65.00 |
| David Westenberg | Piper Sandler | Lowers | Overweight | $75.00 | $85.00 |
| Patrick Donnelly | Citigroup | Lowers | Buy | $75.00 | $80.00 |
| Brandon Couillard | Jefferies | Raises | Buy | $85.00 | $84.00 |
| Mark Massaro | BTIG | Lowers | Buy | $65.00 | $82.00 |
| Daniel Arias | Stifel | Lowers | Buy | $67.00 | $82.00 |
| Kyle Mikson | Canaccord Genuity | Lowers | Buy | $75.00 | $95.00 |
| Dan Brennan | TD Cowen | Lowers | Buy | $82.00 | $90.00 |
| Matthew Sykes | Goldman Sachs | Lowers | Buy | $65.00 | $75.00 |
| Vijay Kumar | Evercore ISI Group | Lowers | Outperform | $60.00 | $80.00 |
| Alex Nowark | Craig-Hallum | Lowers | Buy | $65.00 | $82.00 |
| Bruce Jackson | Benchmark | Lowers | Buy | $65.00 | $67.00 |
| Catherine Schulte | Baird | Lowers | Outperform | $67.00 | $70.00 |
| Eve Burstein | Bernstein | Raises | Outperform | $90.00 | $75.00 |
| Kyle Mikson | Canaccord Genuity | Raises | Buy | $95.00 | $75.00 |
| Vijay Kumar | Evercore ISI Group | Raises | Outperform | $80.00 | $72.00 |
| Kyle Mikson | Canaccord Genuity | Maintains | Buy | $75.00 | $75.00 |
| David Westenberg | Piper Sandler | Raises | Overweight | $85.00 | $75.00 |
Key Insights:
- Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Exact Sciences. This insight gives a snapshot of analysts' perspectives on the current state of the company.
- Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Exact Sciences compared to the broader market.
- Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Exact Sciences's stock. This examination reveals shifts in analysts' expectations over time.
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Exact Sciences's market standing. Stay informed and make data-driven decisions with our Ratings Table.
Stay up to date on Exact Sciences analyst ratings.
Get to Know Exact Sciences Better
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a precancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
Exact Sciences: Delving into Financials
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Positive Revenue Trend: Examining Exact Sciences's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 12.78% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Exact Sciences's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -5.4%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -1.19%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -0.57%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Exact Sciences's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.86.
Analyst Ratings: Simplified
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in Benzinga Pro.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
